Related references
Note: Only part of the references are listed.Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
Samuel J. Klempner et al.
ONCOLOGIST (2020)
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Updated results from phase I/Ib IVY study.
Aung Naing et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy
Jun-Jun Wu et al.
MEDICINAL RESEARCH REVIEWS (2020)
Checkpoint inhibitor immunotherapy in kidney cancer
Wenxin Xu et al.
NATURE REVIEWS UROLOGY (2020)
Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
Lucia Carril-Ajuria et al.
CANCERS (2020)
Human Endogenous Retroviruses (HERVs): Shaping the Innate Immune Response in Cancers
Vincent Alcazer et al.
CANCERS (2020)
Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
Kenji Ichikawa et al.
SCIENTIFIC REPORTS (2020)
Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression
Qing Liu et al.
CELL COMMUNICATION AND SIGNALING (2020)
MP18-07 HIGH EXPRESSION OF TUMOR-ASSOCIATED MACROPHAGE (TAM) MARKERS WITHIN THE TUMOR MICROENVIRONMENT SIGNALS POOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY
Ahmet M Aydin* et al.
JOURNAL OF UROLOGY (2020)
Pancreatic tropism of metastatic renal cell carcinoma
Nirmish Singla et al.
JCI INSIGHT (2020)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2019)
Immune infiltration in renal cell carcinoma
Shichao Zhang et al.
CANCER SCIENCE (2019)
The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB).
A. Ari Hakimi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Regulatory T cells in cancer immunosuppression - implications for anticancer therapy
Yosuke Togashi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PTEN Mutations Trigger Resistance to Immunotherapy
Feixiong Cheng et al.
TRENDS IN MOLECULAR MEDICINE (2019)
Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma
Svenja Bihr et al.
NEOPLASIA (2019)
The role of cytokines in the regulation of NK cells in the tumor environment
Gordana M. Konjevic et al.
CYTOKINE (2019)
Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).
Sarah Abou Alaiwi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel et al.
CANCER DISCOVERY (2019)
Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma
Botao Fa et al.
EBIOMEDICINE (2019)
Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
Antonino Bruno et al.
FRONTIERS IN IMMUNOLOGY (2019)
Macrophage-Mediated Subversion of Anti-Tumour Immunity
Valeria Quaranta et al.
CELLS (2019)
MMP-9 secreted by tumor associated macrophages promoted gastric cancer metastasis through a PI3K/AKT/Snail pathway
Lin Liu et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
VEGF and FGF-2: Promising targets for the treatment of respiratory disorders
Ankit P. Laddha et al.
RESPIRATORY MEDICINE (2019)
NK Cell Metabolism and Tumor Microenvironment
Inigo Terren et al.
FRONTIERS IN IMMUNOLOGY (2019)
Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
David A. Braun et al.
JAMA ONCOLOGY (2019)
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
Crescenzo D'Alterio et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Kidney Cancer, Version 2.2020 Featured Updates to the NCCN Guidelines
Robert J. Motzer et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
Charlotte M. Huijts et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial
A. Ari Hakimi et al.
CANCER DISCOVERY (2019)
Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer
Eleni-Kyriaki Vetsika et al.
CELLS (2019)
Role of Matrix Metalloproteinases in Angiogenesis and Cancer
Saray Quintero-Fabian et al.
FRONTIERS IN ONCOLOGY (2019)
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Priti S. Hegde et al.
SEMINARS IN CANCER BIOLOGY (2018)
Genetic and metabolic hallmarks of clear cell renal cell carcinoma
Danielle J. Sanchez et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
Robert D. Leone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing
Deng Pan et al.
SCIENCE (2018)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao et al.
SCIENCE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory factors
Tao Wang et al.
CANCER DISCOVERY (2018)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Christopher J. Ricketts et al.
CELL REPORTS (2018)
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Ilaria Grazia Zizzari et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
Adriana Albini et al.
FRONTIERS IN IMMUNOLOGY (2018)
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Rebekka Weber et al.
FRONTIERS IN IMMUNOLOGY (2018)
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Viktor Fleming et al.
FRONTIERS IN IMMUNOLOGY (2018)
Targeting adenosine for cancer immunotherapy
Robert D. Leone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Adenosinergic signaling as a target for natural killer cell immunotherapy
Jiao Wang et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2018)
The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment
Katharina Helene Susek et al.
FRONTIERS IN IMMUNOLOGY (2018)
Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
Christof C. Smith et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
The Immunobiology of Kidney Cancer
Charles G. Drake et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity
Anna Maria Trotta et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Maria Georganaki et al.
FRONTIERS IN IMMUNOLOGY (2018)
Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer
Franziska Eckert et al.
FRONTIERS IN IMMUNOLOGY (2018)
Interleukin-6 induces drug resistance in renal cell carcinoma
Kei Ishibashi et al.
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE (2018)
Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors
Luca Cassetta et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2018)
Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α
Yana G. Najjar et al.
CLINICAL CANCER RESEARCH (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
Immunological effects of everolimus in patients with metastatic renal cell cancer
Charlotte M. Huijts et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
Teresa Davoli et al.
SCIENCE (2017)
Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
Takuto Hara et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade
Kei Ishibashi et al.
ONCOTARGET (2017)
Targeting iNOS to increase efficacy of immunotherapies
Suhendan Ekmekcioglu et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Jeremy B. Foote et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor immunity, immunosuppression, or Bystander Sentinels in Disease?
Emily Jayne Colbeck et al.
FRONTIERS IN IMMUNOLOGY (2017)
Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.
Lawrence Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
Heather J Dalton et al.
CLINICAL CANCER RESEARCH (2017)
Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma
Nicolas A. Giraldo et al.
CLINICAL CANCER RESEARCH (2017)
An Immune Atlas of Clear Cell Renal Cell Carcinoma
Stephane Chevrier et al.
CELL (2017)
Targeting amino acid metabolism for cancer therapy
Michael J. Lukey et al.
DRUG DISCOVERY TODAY (2017)
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Haidong Tang et al.
CANCER CELL (2016)
Loss of PTEN promotes resistance to T cell-mediated immunotherapy
Weiyi Peng et al.
CANCER RESEARCH (2016)
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Chan-Young Ock et al.
CLINICAL CANCER RESEARCH (2016)
Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer
David R. Kroeger et al.
CLINICAL CANCER RESEARCH (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2016)
MDSC trafficking and function in RCC by CXCR4 in the presence of a VEGF-R antagonist is dependent on HIF-2α expression
D. J. Panka et al.
EUROPEAN JOURNAL OF CANCER (2016)
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status
Yosra Messai et al.
EUROPEAN UROLOGY (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
Holger Moch et al.
EUROPEAN UROLOGY (2016)
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma
Alberto Farolfi et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers
Marie-Caroline Dieu-Nosjean et al.
IMMUNOLOGICAL REVIEWS (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma
Hirokazu Matsushita et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
Yu -Ling Li et al.
CANCER BIOLOGY & MEDICINE (2016)
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures
Yasin Senbabaoglu et al.
GENOME BIOLOGY (2016)
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Benoit Beuselinck et al.
CLINICAL CANCER RESEARCH (2015)
Activation-Specific Metabolic Requirements for NK Cell IFN-γ Production
Molly P. Keppel et al.
JOURNAL OF IMMUNOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Su-Jin Shin et al.
ONCOLOGIST (2015)
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
Xian-De Liu et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages
Leslie Chavez-Galan et al.
FRONTIERS IN IMMUNOLOGY (2015)
Clinical blockade of PD1 and LAG3-potential mechanisms of action
Linh T. Nguyen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells
Jeremy Goc et al.
CANCER RESEARCH (2014)
Myeloid WNT7b Mediates the Angiogenic Switch and Metastasis in Breast Cancer
Eun-Jin Yeo et al.
CANCER RESEARCH (2014)
NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention
Petra U. Prinz et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
IL-6-Mediated Induction of Matrix Metalloproteinase-9 Is Modulated by JAK-Dependent IL-10 Expression in Macrophages
Poonam Kothari et al.
JOURNAL OF IMMUNOLOGY (2014)
Endogenous Retroviruses and the Development of Cancer
George Kassiotis
JOURNAL OF IMMUNOLOGY (2014)
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger et al.
NATURE GENETICS (2014)
Tertiary lymphoid structures in cancer and beyond
Marie-Caroline Dieu-Nosjean et al.
TRENDS IN IMMUNOLOGY (2014)
SETD2-Dependent Histone H3K36 Trimethylation Is Required for Homologous Recombination Repair and Genome Stability
Sophia X. Pfister et al.
CELL REPORTS (2014)
Role of tumor assocaited macrophages in tumor angiogenesis and lymphangiogenesis
Vladimir Riabov et al.
FRONTIERS IN PHYSIOLOGY (2014)
The role IL-1 in tumor-mediated angiogenesis
Elena Voronov et al.
FRONTIERS IN PHYSIOLOGY (2014)
The PT N/PI3K/AKT pathway in vivo, cancer mouse models
Amancio Carnero et al.
FRONTIERS IN ONCOLOGY (2014)
Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin
Romain Remark et al.
CLINICAL CANCER RESEARCH (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells
Zaheed Husain et al.
JOURNAL OF IMMUNOLOGY (2013)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
Neuropilin 1 guides regulatory T cells into VEGF-producing melanoma
Wiebke Hansen
ONCOIMMUNOLOGY (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Distinctive Features of the Differentiated Phenotype and Infiltration of Tumor-Reactive Lymphocytes in Clear Cell Renal Cell Carcinoma
Qiong J. Wang et al.
CANCER RESEARCH (2012)
Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics
W. Marston Linehan
GENOME RESEARCH (2012)
The mTOR Signalling Pathway in Human Cancer
Helena Populo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Targeting Costimulatory Molecules to Improve Antitumor Immunity
Daria Capece et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa
Eric T. Clambey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Tumor associated regulatory dendritic cells
Yang Ma et al.
SEMINARS IN CANCER BIOLOGY (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Human Renal Cell Carcinoma Induces a Dendritic Cell Subset That Uses T-Cell Crosstalk for Tumor-Permissive Milieu Alterations
Ainhoa-M. Figel et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC)
Chenghai Li et al.
CANCER BIOLOGY & THERAPY (2011)
Targeting Regulatory T Cells in Cancer
William L. Byrne et al.
CANCER RESEARCH (2011)
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma
Yoshihiro Komohara et al.
CANCER SCIENCE (2011)
Anti-VEGF Treatment-Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype
Carmine Carbone et al.
CLINICAL CANCER RESEARCH (2011)
mTOR Inhibitors in Advanced Renal Cell Carcinoma
Martin H. Voss et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2011)
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
James Finke et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB-Cytokine Network
Haoqiang Ying et al.
CANCER DISCOVERY (2011)
Macrophage Expression of Hypoxia-Inducible Factor-1α Suppresses T-Cell Function and Promotes Tumor Progression
Andrew L. Doedens et al.
CANCER RESEARCH (2010)
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Sergei I. Grivennikov et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
Cesar A. Corzo et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Increase of Circulating CD4+CD25highFoxp3+ Regulatory T Cells in Patients With Metastatic Renal Cell Carcinoma During Treatment With Dendritic Cell Vaccination and Low-Dose Interleukin-2
Annika Berntsen et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Marcin Kortylewski et al.
CANCER CELL (2009)
Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via L-Arginine Metabolism
Lyse A. Norian et al.
CANCER RESEARCH (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Chemokines and chemokine receptors: an overview
Raffaella Bonecchi et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
CXCL8/IL8 Stimulates Vascular Endothelial Growth Factor (VEGF) Expression and the Autocrine Activation of VEGFR2 in Endothelial Cells by Activating NFκB through the CBM (Carma3/Bcl10/Malt1) Complex
Daniel Martin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Tumor-Educated CD11bhighIalow Regulatory Dendritic Cells Suppress T Cell Response through Arginase I
Qiuyan Liu et al.
JOURNAL OF IMMUNOLOGY (2009)
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization
Karen H. Ventii et al.
CANCER RESEARCH (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
Targeting vessels to treat hepatocellular carcinoma
Pamela Romanque et al.
CLINICAL SCIENCE (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Farbod Shojaei et al.
NATURE BIOTECHNOLOGY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma
Sameer A. Siddiqui et al.
CLINICAL CANCER RESEARCH (2007)
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
Emmanuel Zorn et al.
BLOOD (2006)
Impact of immune parameters on long-term survival in metastatic renal cell carcinoma
F Donskov et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines
T Pukrop et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors
Anita E. M. Dirkx et al.
FASEB JOURNAL (2006)
Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Overview of interleukin-2 function, production and clinical applications
SL Gaffen et al.
CYTOKINE (2004)
Share Paper
